These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15103802)

  • 1. Nursing initiatives for deep vein thrombosis prophylaxis. Pragmatic timing of administration.
    Morris B
    Orthop Nurs; 2004; 23(2):142-7; quiz 148-9. PubMed ID: 15103802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
    Whang PG; Lieberman JR
    Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with ximelagatran in orthopaedic surgery.
    Eriksson B
    Drugs; 2004; 64 Suppl 1():27-35. PubMed ID: 15586625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Standards and perspectives for thromboembolism prophylaxis].
    Rader CP
    Orthopade; 2007 Jun; 36(6):560, 562-6. PubMed ID: 17546440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review.
    Hull RD; Pineo GF; Stein PD; Mah AF; MacIsaac SM; Dahl OE; Butcher M; Brant RF; Ghali WA; Bergqvist D; Raskob GE
    Ann Intern Med; 2001 Nov; 135(10):858-69. PubMed ID: 11712876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deep vein thrombosis prophylaxis: better living through chemistry--in the affirmative.
    Kwong LM
    J Arthroplasty; 2005 Jun; 20(4 Suppl 2):12-4. PubMed ID: 15991121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.
    Freedman KB; Brookenthal KR; Fitzgerald RH; Williams S; Lonner JH
    J Bone Joint Surg Am; 2000 Jul; 82-A(7):929-38. PubMed ID: 10901307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of venous thromboembolic disease after total hip and knee arthroplasty.
    Lieberman JR; Hsu WK
    J Bone Joint Surg Am; 2005 Sep; 87(9):2097-112. PubMed ID: 16140827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep vein thrombosis prophylaxis: a comprehensive approach for total hip and total knee arthroplasty patient populations.
    Miric A; Lombardi P; Sculco TP
    Am J Orthop (Belle Mead NJ); 2000 Apr; 29(4):269-74. PubMed ID: 10784014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Benefit/risk ratio analysis from a possible anticoagulation of asymptomatic deep venous thrombosis in major orthopedic surgery].
    Barrellier MT; Samama CM
    J Mal Vasc; 2013 May; 38(3):178-84. PubMed ID: 23415379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based evaluation of preoperative vs postoperative use of low-molecular-weight heparin in preventing deep vein thrombosis in elective hip surgery.
    Ghosh A
    Arch Intern Med; 1999 Jul; 159(14):1622-3. PubMed ID: 10421287
    [No Abstract]   [Full Text] [Related]  

  • 12. Continuing out-of-hospital prophylaxis following major orthopaedic surgery: what now?
    Dahl OE
    Haemostasis; 2000; 30 Suppl 2():101-5; discussion 82-3. PubMed ID: 11251351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a nomogram and physician-adjusted dosage of warfarin for prophylaxis against deep-vein thrombosis after arthroplasty.
    Anderson DR; Wilson SJ; Blundell J; Petrie D; Leighton R; Stanish W; Alexander D; Robinson KS; Burton E; Gross M
    J Bone Joint Surg Am; 2002 Nov; 84(11):1992-7. PubMed ID: 12429760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular-weight heparin for deep vein thrombosis prophylaxis in foot and ankle surgery: a review.
    Cirlincione AS; Mendicino R; Catanzariti AR; Grossman J
    J Foot Ankle Surg; 2001; 40(2):96-100. PubMed ID: 11324676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparin versus other anti-thrombotic agents for prevention of venous thromboembolic events after total hip or total knee replacement surgery: a systematic review and meta-analysis.
    Lu X; Lin J
    BMC Musculoskelet Disord; 2018 Sep; 19(1):322. PubMed ID: 30193575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Summaries for patients. Low-molecular-weight heparin given for several weeks after hip surgery prevents deep venous thrombosis.
    Ann Intern Med; 2001 Nov; 135(10):S-55. PubMed ID: 11757493
    [No Abstract]   [Full Text] [Related]  

  • 18. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.
    Jameson SS; Rymaszewska M; Hui AC; James P; Serrano-Pedraza I; Muller SD
    J Bone Joint Surg Am; 2012 Sep; 94(17):1554-8. PubMed ID: 22832942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thromboembolism prophylaxis after hospital discharge: transition to preventive care.
    Kaatz S; Spyropoulos AC
    Hosp Pract (1995); 2011 Aug; 39(3):7-15. PubMed ID: 21881387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.